Abstract
Murine hematopoietic stem cells (HSC) transfected with a gain-of-function human erythropoietic receptor (EPOR) transgene were reported to have a competitive advantage over wild type mouse hematopoietic stem cells in a bone marrow transplantation (BMT) model (
Because unequal numbers of HSC may result in skewed chimerism, we examined the relative proportions of HSC to total bone marrow cells. In wthEPOR mice, the Flt3− Rh123low subset of cKit+Sca1+ cells (KLS-FS) cells represented 0.011±0.003% of total bone marrow cells while in mthEPOR mice these cells represented 0.023±0.006% of total bone marrow cells (p=0.025). Since equal numbers of wthEPOR and mthEPOR total bone marrow cells were co-transplanted, relatively fewer wthEPOR HSC than mthEPOR HSC were transferred. Taken with the above chimerism data showing skewing towards wthEPOR, these results suggest that wthEPOR HSCs have a significant engraftment advantage over mthEPOR HSCs. Furthermore, enhanced Epo/EpoR signaling may interfere with the long term repopulation of hematopoietic progenitors. Hematopoietic stem cells undergo self renewal or differentiation/proliferation; in the presence of erythropoietin, a cytokine with proliferative and differentiating properties, it may be that self renewal is suppressed leading ultimately to the observed skewed chimerism. These data suggest that erythropoietin administration to patients during and immediately after marrow transplantation may be detrimental and should be used judiciously.
Compartment . | wthEPOR (CD45.1) . | mthEPOR (CD45.2) . | Endogenous control (CD45.1/CD45.2) . |
---|---|---|---|
All p values for wthEPOR vs mthEPOR < 0.01 | |||
Neutrophil (blood) | 72.7% | 18.8% | 8.5% |
Macrophage (blood) | 76.8% | 14.7% | 8.5% |
T cell (blood) | 78.6% | 9.3% | 12.2% |
B cell (blood) | 72.8% | 17.7% | 9.5% |
HSC (marrow) | 66% | 15.1% | 18.9% |
Compartment . | wthEPOR (CD45.1) . | mthEPOR (CD45.2) . | Endogenous control (CD45.1/CD45.2) . |
---|---|---|---|
All p values for wthEPOR vs mthEPOR < 0.01 | |||
Neutrophil (blood) | 72.7% | 18.8% | 8.5% |
Macrophage (blood) | 76.8% | 14.7% | 8.5% |
T cell (blood) | 78.6% | 9.3% | 12.2% |
B cell (blood) | 72.8% | 17.7% | 9.5% |
HSC (marrow) | 66% | 15.1% | 18.9% |
Disclosure: No relevant conflicts of interest to declare.
Author notes
Corresponding author
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal